PRQR ProQR Therapeutics N.V

$PRQR dr. Haussecker on x $ARWR HAS TO buy either $KRRO or $PRQR as the CNS holds huge value for RNAediting (targets and enzymatic activity) and delivery can be easily adapted.

$PRQR $WVE $ALNY John Maraganore, original founder/CEO of ALNY from 2002-2022, is the founder of new siRNA player $CTY. Maraganore is an active strategic advisor to the PRQR board of directors for corp pipeline strategy/business development since 2022. $WVE currently has 4 active clinical programs in Phase 2. It's hard to understand enterprise values for $PRQR at $80M and $WVE at $175M . These RNA companies have been partnered for development with Lilly and GSK going on 4-5 years now. PRQR and WVE don't disclose these programs or preclinical developments because they want to keep them quiet for competitive reasons.

$PRQR $WVE $ADRX Also some more tidbits on ADRX - they were launched in 2019 - 7 years ago. (mostly explains why new candidates for PRQR/LLY and WVE/GSK collaborations haven’t been disclosed.) The original private investors in ADRX were Lilly Asia Ventures, Orbimed, Bain and TCG among others. All of these private specialists bought into the ADRX IPO - except for LLY, very interesting. Abbie was the big pharma company that bought into this IPO. PRQR and WVE have been partnered for development with Lilly and GSK going on 4-5 years now. Will remind you that LLY has bought into all of PRQR’s capital raises since 2022. GSK has bought into WVE’s raises since 2022, including the deal last December at $19.00 per share - this valued WVE at $3.6B 10 months ago. Insane. I suspect ADRX and CTY IPOs have something to do with the destroyed valuations for early leaders in RNA editing.

$PRQR I’m increasingly convinced — just my opinion — that AASLD’s Liver Meeting (Nov 5–9) could be where ProQR presents the full AX-0810 Phase 1 dataset, including 9 mg/kg and 12-week follow-up. The timing fits unusually well: late-breaker submissions closed Sep 25, and abstracts are now under blinded peer review by ≥4 reviewers before Scientific Program Committee selection. Late-breaking Phase 1 trials are eligible (poster only), with the embargo lifting Nov 5. Nothing confirmed yet, but the pieces line up.

$PRQR brought on Chris Hart as chief data and AI officer and Thomas Wolf as strategic AI advisor to its board.

$PRQR i was shocked to see the sp of $WVE dropped to low 3$. Less than a quarter at which I let them go. That’s a lot worse than $PRQR.

$PRQR quickly headed toward the 2026 yearly low. These guys just can’t generate any interest, momentum, enthusiasm, you name it. Whatever it takes we certainly don’t have it.

$PRQR below every recent insider buy. 50% below LLY avg price per share not including upfront or milestones. You should all sell your positions now while the fake funds blow up.

$PRQR saw some interesting action today A buyer snapped up about 6.4K April 2027 calls at the $7.50 strike, way out of the money, with a $130K premium on InsiderFinance This is far above current open interest, signaling fresh upside plays Implied volatility is high, around 135 to 175 percent, with contracts about 186 days out Feels more like a long shot gamble than a clear directional bet PRQR barely moved, down about 0.6 percent over both 1D and 5D No news backing this up, so it's all about waiting for price or volume to confirm anything serious Stay cautious

$PRQR yeah but wve hired a guy who can token max on chat gpt prompts, all we have is a lousy hugging face cofounder.

$PRQR currently lists 9 open positions, including 6 in clinical development and regulatory affairs, 2 in R&D, and 1 in operations. Notably, the company is recruiting senior regulatory, clinical operations, biostatistics, and toxicology professionals. This suggests ProQR is strengthening its infrastructure to support multiple Axiomer programs entering clinical development. A potentially encouraging operational signal, although hiring alone does not confirm positive clinical results.

$PRQR Takeaways from ProQR’s BA event: -AX-0811 is currently expected to advance into the China pediatric IIT, subject to January data. -Human PK-based modeling predicts ~40% editing at 2 mg/kg and ~65% at 4 mg/kg, with less frequent dosing. -Importantly, higher NTCP expression in BA patients may enhance editing versus healthy volunteers. -The IIT will test whether target engagement translates into reduced cholestatic liver injury and fibrosis. -ProQR is also discussing with regulators a potential path combining biomarkers, imaging and clinical outcomes, possibly supported by external/registry controls.

$PRQR what percentage of the company do you own? Ie. take an ownership perspective instead of thinking like a stupid trader

$PRQR -Lilly has invested approximately $150 million in prqr and owns 22,000,000 shares-15.6 %.

$PRQR I think we have around 140m. At this rate we should be trading at cash value sometime next week 🤦

$PRQR Guess Charles and Schwab know what they’re doing when they put restrictions on a ticker :). We may see 1.3s or even lower at this rate.

$PRQR for anyone not familiar, it look like I wrote "we've" but I was referring to a ticker for wave life sciences :) Of course it won't let me edit